Financial Performance - Revenue for the year ended December 31, 2025, was RMB 4,887,777, an increase of 4.7% compared to RMB 4,669,078 in 2024[3] - The net loss for the year narrowed to RMB 52,111, a reduction of 86.3% from RMB 379,986 in the previous year[3] - Adjusted net profit for the year was RMB 10,684, an increase of approximately RMB 67.9 million compared to a loss of RMB 57,228 in 2024[3] - The adjusted net profit margin improved to 0.2%, up 1.4 percentage points from a loss margin of 1.2% in 2024[3] - Total revenue for 2025 reached RMB 4,887.8 million, a year-on-year increase of 4.7% from RMB 4,669.1 million in 2024[12] - The company's net loss was reduced to RMB 52.1 million, with adjusted net profit of RMB 10.7 million, which could further increase to RMB 22.6 million after excluding foreign exchange losses of RMB 11.9 million[12] - Gross margin improved to 35.3%, an increase of 2.4 percentage points year-on-year, indicating enhanced profitability[12] - The adjusted net profit reflects the effectiveness of refined operations and cost reduction strategies, indicating potential for continued improvement in profitability[12] - The net loss is expected to decrease by 86.3% from RMB 380.0 million for the year ending December 31, 2024, to RMB 52.1 million for the year ending December 31, 2025[36] - Adjusted net profit/loss (non-IFRS measure) is projected to improve from a loss of RMB 57.2 million in 2024 to a profit of RMB 10.7 million in 2025, with the adjusted net profit margin increasing from -1.2% to 0.2%[39] Revenue Breakdown - Online direct sales revenue was RMB 3,551.2 million, up 8.4% from RMB 3,274.6 million in 2024, while offline retail revenue increased by 3.9% to RMB 646.5 million[14] - Revenue from pharmaceutical and healthcare business rose by 4.5% to RMB 4,744.6 million from RMB 4,539.6 million in 2024[23] - Business distribution revenue decreased by 14.9% to RMB 546.9 million from RMB 642.8 million in 2024[16] - Offline retail revenue increased by 3.9% to RMB 646.5 million compared to RMB 622.2 million in 2024[17] - Other business revenue grew by 10.6% to RMB 143.2 million from RMB 129.5 million in 2024[18] Operational Strategies - The company is focusing on enhancing its digital health services and expanding its AI-driven health management capabilities[6] - The establishment of four intelligent warehouses across different regions aims to achieve 24-hour efficient operations[6] - The company plans to strengthen its core city health services and support long-term profitability through timely health delivery services[8] - AI technology will be deeply integrated into the health service retail chain, transitioning from passive selling to proactive health management[7] - The company is committed to a strategy of "steady operation and high-quality growth," emphasizing product strength, channel power, innovation, professionalism, and organizational capability[8] - The company aims to leverage data resources and technological advantages to expand the boundaries of intelligent applications in health services[6] - The company is focusing on optimizing its supply chain and logistics capabilities, particularly in specialized areas such as diabetes and dermatology, to enhance user service and ensure safe medication[14] - The company is actively expanding its smart pharmacy network in key cities like Beijing, Shanghai, and Shenzhen, aiming to strengthen its market presence[13] - The company is pursuing a strategy that combines health management and retail services, focusing on innovative health products and services[13] Expenses and Financial Management - Sales and marketing expenses are expected to increase by 8.5% from RMB 1,013.3 million for the year ending December 31, 2024, to RMB 1,099.4 million for the year ending December 31, 2025, with the percentage of revenue rising from 21.7% to 22.5%[27] - Research and development expenses are projected to decrease by 11.1% from RMB 61.2 million for the year ending December 31, 2024, to RMB 54.4 million for the year ending December 31, 2025, with the percentage of revenue declining from 1.3% to 1.1%[28] - General and administrative expenses are expected to decrease by 24.4% from RMB 229.7 million for the year ending December 31, 2024, to RMB 173.6 million for the year ending December 31, 2025, with the percentage of revenue falling from 4.9% to 3.6%[29] - Financial costs are expected to increase by 39.3% from RMB 8.9 million for the year ending December 31, 2024, to RMB 12.4 million for the year ending December 31, 2025[32] - Income tax expenses are projected to increase by 116.2% from RMB 9.9 million for the year ending December 31, 2024, to RMB 21.4 million for the year ending December 31, 2025, mainly due to an increase in taxable income[35] Assets and Liabilities - Total assets increased to RMB 2,834,171 thousand in 2025 from RMB 2,632,675 thousand in 2024, showing a growth of approximately 7.6%[49] - Current assets totaled RMB 2,135,984 thousand in 2025, slightly down from RMB 2,201,613 thousand in 2024, a decrease of about 3%[46] - The company reported a total equity of RMB 1,674,909 thousand in 2025, a slight decrease from RMB 1,680,230 thousand in 2024[49] - The total liabilities increased to RMB 1,159,262 thousand in 2025 from RMB 952,445 thousand in 2024, an increase of about 21.7%[49] - The company’s cash and cash equivalents decreased to RMB 429,323 thousand in 2025 from RMB 1,217,954 thousand in 2024, a decline of approximately 64.7%[46] Shareholder Information - The company did not declare or recommend any dividends to ordinary shareholders for the year ended December 31, 2025, consistent with the previous year[77] - The company has implemented a share incentive plan involving a total of 87,993,330 shares, representing approximately 6.8% of the total issued share capital as of December 31, 2025[98] - The company has repurchased a total of 9,256,500 shares at a total cost of approximately 10.0 million HKD, aimed at enhancing long-term shareholder value[105] - The company will not recommend a final dividend for the year ending December 31, 2025, consistent with the previous year[108] Compliance and Governance - The company has maintained compliance with corporate governance standards and has adopted the relevant rules from the Hong Kong Stock Exchange[101] - The group has established an audit committee consisting of three independent non-executive directors, with Mr. Jiang Shan as the chairman[111] - The audit committee has reviewed the audited consolidated financial statements for the year ending December 31, 2025, and discussed accounting policies and internal controls with senior management and the auditors[112] - The annual performance announcement will be published on the Hong Kong Stock Exchange and the company's website, with the annual report to be sent to shareholders upon request[113]
叮当健康(09886) - 2025 - 年度业绩